JP2022519583A5 - - Google Patents
Info
- Publication number
- JP2022519583A5 JP2022519583A5 JP2021544901A JP2021544901A JP2022519583A5 JP 2022519583 A5 JP2022519583 A5 JP 2022519583A5 JP 2021544901 A JP2021544901 A JP 2021544901A JP 2021544901 A JP2021544901 A JP 2021544901A JP 2022519583 A5 JP2022519583 A5 JP 2022519583A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- exosome
- aggregation
- detecting
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024207019A JP2025029000A (ja) | 2019-01-31 | 2024-11-28 | 神経変性疾患を検出する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201900940Y | 2019-01-31 | ||
| SG10201900940Y | 2019-01-31 | ||
| PCT/IB2020/050764 WO2020157705A1 (en) | 2019-01-31 | 2020-01-30 | Method of detecting a neurodegenerative disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207019A Division JP2025029000A (ja) | 2019-01-31 | 2024-11-28 | 神経変性疾患を検出する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519583A JP2022519583A (ja) | 2022-03-24 |
| JP2022519583A5 true JP2022519583A5 (enExample) | 2023-02-02 |
Family
ID=71841387
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544901A Pending JP2022519583A (ja) | 2019-01-31 | 2020-01-30 | 神経変性疾患を検出する方法 |
| JP2024207019A Pending JP2025029000A (ja) | 2019-01-31 | 2024-11-28 | 神経変性疾患を検出する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207019A Pending JP2025029000A (ja) | 2019-01-31 | 2024-11-28 | 神経変性疾患を検出する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220397580A1 (enExample) |
| EP (1) | EP3918327A4 (enExample) |
| JP (2) | JP2022519583A (enExample) |
| CN (2) | CN113614531A (enExample) |
| SG (1) | SG11202107238UA (enExample) |
| WO (1) | WO2020157705A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120121584A (zh) | 2019-01-31 | 2025-06-10 | 新加坡国立大学 | 传感器芯片及其方法 |
| EP4428245A4 (en) * | 2021-11-04 | 2025-04-02 | Toppan Holdings Inc. | Method for detecting amyloid-beta bound to brain-neuronal-cell-derived exosome in blood, kit for detection of amyloid-beta bound to brain-neuronal-cell-derived exosome in blood, and method for evaluating accumulation level of amyloid-beta in brain |
| WO2023232108A1 (zh) * | 2022-06-02 | 2023-12-07 | 浙江大学医学院附属第一医院 | 诊断及鉴别诊断非阿尔兹海默病认知障碍的方法、系统、组合物和试剂盒 |
| WO2025117465A1 (en) * | 2023-11-27 | 2025-06-05 | New York University | Tau is a low affinity receptor of glucocorticoid and needed for glucocorticoid-caused bone loss |
| WO2025122650A1 (en) * | 2023-12-04 | 2025-06-12 | Sunbird Bio, Inc. | Extracellular vesicle-based biomarker detection |
| CN118348260B (zh) * | 2024-05-13 | 2025-02-25 | 香港中文大学（深圳） | 一种帕金森病诊断标志物组合及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2963791B1 (fr) * | 2010-08-11 | 2012-09-21 | Assist Publ Hopitaux De Paris | Methode de diagnostic des maladies neurodegeneratives |
| US20140256793A1 (en) * | 2011-10-14 | 2014-09-11 | National University Corporation Hokkaido University | MEDICAMENT FOR DISEASES ASSOCIATED WITH AMYLOID beta AND SCREENING THEREOF |
| CA2926092A1 (en) * | 2013-10-24 | 2015-04-30 | Nanosomix, Inc. | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders |
| CN106062559B (zh) * | 2014-06-27 | 2018-12-14 | 北京新源长青生物科技有限公司 | 用于富集cns来源的外泌体的方法 |
| EP3307890A1 (en) * | 2015-06-10 | 2018-04-18 | Board of Regents, The University of Texas System | Use of exosomes for the treatment of disease |
| EP3377895B1 (en) * | 2015-11-20 | 2021-07-21 | Exosome Sciences, Inc. | Exosomal tau as a biomarker for brain disorders |
| WO2017124000A1 (en) * | 2016-01-14 | 2017-07-20 | The Regents Of The University Of California | 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids |
| WO2017193115A1 (en) * | 2016-05-06 | 2017-11-09 | Nanosomix, Inc. | Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders |
| KR102048987B1 (ko) * | 2017-02-22 | 2019-11-27 | 한국과학기술연구원 | 신경퇴행성 장애의 진단을 위한 정보 제공 방법 |
| JP7399712B2 (ja) * | 2017-05-24 | 2023-12-18 | ナノソミックス・インコーポレイテッド | 疾病および障害の診断および予後判定のための小胞上のバイオマーカーの検出 |
-
2020
- 2020-01-30 CN CN202080012032.7A patent/CN113614531A/zh active Pending
- 2020-01-30 JP JP2021544901A patent/JP2022519583A/ja active Pending
- 2020-01-30 CN CN202510593175.6A patent/CN120870569A/zh active Pending
- 2020-01-30 EP EP20749564.9A patent/EP3918327A4/en active Pending
- 2020-01-30 US US17/310,253 patent/US20220397580A1/en not_active Abandoned
- 2020-01-30 SG SG11202107238UA patent/SG11202107238UA/en unknown
- 2020-01-30 WO PCT/IB2020/050764 patent/WO2020157705A1/en not_active Ceased
-
2024
- 2024-11-28 JP JP2024207019A patent/JP2025029000A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519583A5 (enExample) | ||
| Dutta et al. | Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges | |
| Schwarz et al. | Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls | |
| Rogers et al. | Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes | |
| Rani et al. | A novel approach to correlate the salivary exosomes and their protein cargo in the progression of cognitive impairment into Alzheimer’s disease | |
| Savage et al. | A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid | |
| JP6166016B2 (ja) | 生体分子の濃度を測定するための方法 | |
| Nuzzo et al. | Inflammatory mediators as biomarkers in brain disorders | |
| JP6061935B2 (ja) | 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット | |
| JP7734427B2 (ja) | 神経由来エクソソーム中の核酸の検出方法および分析方法 | |
| Vrillon et al. | Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies | |
| Zhang et al. | Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome | |
| JP2022113682A (ja) | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 | |
| US11867702B2 (en) | Detection of pathological protein aggregation | |
| WO2007082750A1 (en) | IMMUNOGLOBULIN-BOUND Aβ-PEPTIDES AND IMMUNOGLOBULINS-BINDING Aβ- PEPTIDES IN DIAGNOSIS AND THERAPY OF ALZHEIMER'S DEMENTIA | |
| JP2024525559A5 (enExample) | ||
| Gong et al. | Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease? | |
| van der Ende et al. | Fluid biomarkers of frontotemporal lobar degeneration | |
| Abbasi et al. | Characterization of the cerebrospinal fluid proteome in patients with fragile X-associated tremor/ataxia syndrome | |
| WO2024074133A1 (en) | Protein marker for assessing and treating neurodegenerative diseases | |
| Wang et al. | Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease | |
| Manzini et al. | miR-92a-3p and miR-320a are upregulated in plasma neuron-derived extracellular vesicles of patients with frontotemporal dementia | |
| Wang et al. | Brain derived β-interferon is a potential player in Alzheimer’s disease pathogenesis and cognitive impairment | |
| Eren et al. | Effects of autologous serum on TREM2 and APOE in a personalized monocyte-derived macrophage assay of late-onset Alzheimer’s patients | |
| Sharma et al. | Bridging the barrier: insights into blood biomarkers and therapeutic strategies targeting choroid plexus and BBB dysfunction in alzheimer’s disease |